PHA Pharmagest Interactive SA

EQUASENS: Acquisition of the German company ADV and creation of PHARMAGEST Germany

EQUASENS: Acquisition of the German company ADV and creation of PHARMAGEST Germany

Villers-lès-Nancy, 23 November 2023 - 6:00 p.m. (CET)

PRESS RELEASE

Acquisition of the German company ADV

and creation of PHARMAGEST Germany

EQUASENS, in partnership with ARZ HAAN, a German market leader for services and software solutions for healthcare providers, acquires ADV (Apotheken Datenverarbeitung GmbH & Co. KG), which becomes PHARMAGEST Germany, through a holding company 6%-held by ARZ HAAN and 94%-held by EQUASENS.

  • PHARMAGEST Germany will invest in developing technology and technical building blocks, as well as a sales network to reinforce ADV's software offering.
  • This acquisition marks a new milestone in the deployment of the growth strategy of EQUASENS, already present in Germany in the medication compliance segment through its subsidiary that markets the MultiMeds pill dispenser and robot. EQUASENS is in this way strengthening its position in the German market in its core pharmacy business.

acquires ADV.

EQUASENS, a leading healthcare software publisher (Euronext Paris™ - Compartment A - ISIN: FR 0012882389 - Ticker: EQS) today announces the acquisition of 100% of the capital of AD Apotheken Datenverarbeitung GmbH & Co. KG (ADV) in partnership with ARZ HAAN.

ADV, founded in 1986, specialises in IT and software solutions for pharmacies. As an independent software vendor, ADV is recognized in Germany for the quality and range of its offering, its customer-focused culture and its ability to adapt its solutions to changing market conditions.

ADV is the developer of the GAWIS business software solution which is based on proven, high-performance technologies offering a comprehensive range of modules and services: dispensing assistance, invoicing, order processing, business intelligence, etc. And in order to meet all needs of the German market, GAWIS is connected to an entire ecosystem of complementary solutions: self-service kiosks and digital shelves, dispensing robots and checkout kiosks. As a result, this software solution is perfectly adapted to the configuration of the German market and also to developments in the German healthcare sector, which, like other European markets, is currently engaged in a digital transformation.

ADV is also the developer of Optipharm pharmacy software, and OPTIPHARM PLUS GmbH, the publisher of this solution is a wholly-owned subsidiary. ADV has already equipped nearly 400 of Germany's 17,500 pharmacies with its two software offerings, GAWIS and Optipharm, despite the absence of a sales team. As of 1 December 2023, ADV thus becomes PHARMAGEST Germany.



ADV's Chief Operating Officer, Rupert SIERP, commented: "With the German healthcare system on the verge of major transformations, ADV is confronted with a number of complex challenges. With EQUASENS as its parent company, ADV will benefit from the support of a solid partner committed to promoting efficiencies in the pharmacy sector. Our existing teams will continue to support ADV and Optipharm users, just as they always have, while benefiting from the active support of EQUASENS’ specialists. In collaboration with EQUASENS, ADV will in this way continue to grow and develop innovative solutions for the German pharmacy market.



Creation of an EQUASENS Germany holding company in partnership with

With nine operating subsidiaries and around 1,000 employees at more than ten locations, ARZ HAAN AG is a leading provider of services to the German healthcare system. Through these specialised subsidiaries, the Group develops and markets innovative service solutions for the healthcare sector. Through its broad range of offerings, from software solutions to digital financing services, the Group supports healthcare professionals in performing their day-to-day activities. More than 17,000 customers, including 4,000 pharmacies, from 30 different professional groups put their trust in the performance and innovative strength of this group of companies.

Philipp Siebelt, spokesman for the ARZ HAAN Group, emphasised: "As an independent company with more than 50 years of service, supporting the core businesses of dispensing pharmacies is the heart of our strategy. The EQUASENS Germany joint venture will allow us to maintain our commitment to the long-term future of Germany's pharmacies.”



A new milestone in the deployment of EQUASENS' strategy in Germany,

The acquisition of ADV, the pharmacy software solutions specialist in Germany, in partnership with ARZ HAAN, a leading provider of services to healthcare professionals, inaugurates Equasens expansion into the German pharmacy management software market.

The contribution of its technologies, the patient-centred approach of its European software solutions and the Group's and business development capabilities will enable PHARMAGEST Germany to become a significant player in this market over the next few years. "Our goal is to become one of the top three software publishers in Germany within the next 5 years by introducing a disruptive solution in a market where digital transformation is rapidly building momentum," concluded Denis Supplisson, Chief Executive Officer of Equasens Group.

About

Founded more than 35 years ago, Equasens Group, which now has more than 1,200 employees in Europe, is the leading publisher of software solutions for the healthcare industry in terms of the diversity of its business applications and market share.

Equasens Group’s specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as financing and training adapted to their specific needs.

And reflecting the spirit of its tagline "more technology for more humanity", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient healthcare system.

Listed on Euronext Paris™ - Compartment A

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable

Included in the Euronext Tech Leaders segment and the European Rising Tech label

Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).

ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about the Equasens Group and on

CONTACTS

Analyst and Investor Relations:

Chief Administrative and Financial Officer: Frédérique Schmidt

Tel.: +33 (0)3 83 15 90 67 -

Financial Press:

FIN’EXTENSO - Isabelle Aprile

Tel.: +33 (0)6 17 38 61 78 –         

Attachment



EN
23/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharmagest Interactive SA

Arnaud Riverain
  • Arnaud Riverain

EQUASENS (EQS) - CA S1 : Retour de la dynamique confirmé / Achat - Obj...

CA S1 +7,4% à 116 M€ en ligne (115,4 M€ attendus) T1 : 57 M€, +6,9% (+5,9% pc) T2 : 58,9 M€, +7,8% (+6,9% pc) Apport de Calimed 1,1 M€ Intégration ResUrgenves & DIS à compter du 1er juillet.

 PRESS RELEASE

Equasens: H1 revenue at 30 June 2025: €116.0m

Equasens: H1 revenue at 30 June 2025: €116.0m Villers-lès-Nancy (France), 31 July 2025 - 6:00 PM (CET) PRESS RELEASE H1 revenue at 30 June 2025: €116.0m+7.4% on a reported basis and +6.4% like-for-like H1 2025 Group revenue (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growth)Q153.357.03.76.9%0.53.25.9%Q254.758.94.37.8%0.53.86.9%Total108.0116.08.07.4%1.16.96.4%H1 2025 revenue / Division (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growthPharmagest82,1...

 PRESS RELEASE

EQUASENS : Chiffre d’affaires au 30 juin 2025 à 116,0 M€

EQUASENS : Chiffre d’affaires au 30 juin 2025 à 116,0 M€ Villers-lès-Nancy, le 31 juillet 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE Chiffre d’affaires au 30 juin 2025 à 116,0 M€+7,4% en croissance publiée et + 6,4% en croissance organique CA S1 2025 Groupe (M€)Publié 2024Publié 2025Variation /publiéDont Croissances externesVariation /périmètre comparable (croissance organique)T153,357,03,76,9%0,53,25,9%T254,758,94,37,8%0,53,86,9%Total108,0116,08,07,4%1,16,96,4%CA S1 2025 / Division (M€)Publié 2024Publié 2025Variation /publiéDont Croissances externesVariation /périmètre comparable (croissan...

 PRESS RELEASE

Equasens: Appointment at the head of the Pharmagest Division

Equasens: Appointment at the head of the Pharmagest Division Villers-lès-Nancy (France), July 03, 2025 – 06 :00pm (CET) Press Release Equasens announces the departure of Damien VALICON, as Deputy Chief Executive Officer and Director of the Pharmagest Division He will be replaced by François-Pierre MARQUIER as Director of the Pharmagest Division. *** (Euronext Paris™ - Compartment B - FR 0012882389 –$EQS), announces the departure of Damien VALICON, who held the position of Deputy Chief Executive Officer and Director of the Pharmagest Division for 18 months, and the appointment of Fran...

 PRESS RELEASE

EQUASENS : Nomination à la direction de la Division Pharmagest

EQUASENS : Nomination à la direction de la Division Pharmagest Villers-lès-Nancy, le 03 juillet 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE Equasens annonce le départ de Damien VALICON, Directeur Général Délégué et Directeur de la Division PHARMAGEST Il sera remplacé par François-Pierre MARQUIER en tant que Directeur de la Division Pharmagest *** (Euronext Paris™ - Compartiment B - FR 0012882389 –$EQS), annonce le départ de Damien VALICON, qui occupait depuis 18 mois les fonctions de Directeur Général Délégué du Groupe et de Directeur de la Division PHARMAGEST, ainsi que la nomination de...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch